Literature DB >> 24499075

AF burden is important - fact or fiction?

G Boriani1, I Diemberger, M Ziacchi, C Valzania, B Gardini, P Cimaglia, C Martignani, M Biffi.   

Abstract

Asymptomatic atrial fibrillation (AF) is common and in view of its prognostic impact (the same as of clinically overt AF) knowledge of the overall AF burden (defined as the amount of time spent in AF) appears to be important, both for scientific and clinical reasons. Data collected on more than 12,000 patients indicate that cardiac implantable electrical devices (CIEDs) are validated tools for measuring AF burden and that AF burden is associated with an increased risk of stroke. A maximum daily AF burden of ≥ 1 h carries important negative prognostic implications and may be a clinically relevant parameter for improving risk stratification for stroke. Decision-making should primarily consider the context in which asymptomatic, subclinical arrhythmias are detected (i.e. primary or secondary prevention of stroke and systemic embolism) and the risk profile of every individual patient with regard to thromboembolic and haemorrhagic risk, as well as patient preferences and values. Continuous monitoring using CIEDs with extensive data storage capabilities allow in-depth study of the temporal relationship between AF and ischaemic stroke. The relationships between AF and stroke are complex. AF is certainly a risk factor for cardioembolic stroke, with a cause-effect relationship between the arrhythmia and a thromboembolic event, the latter being related to atrial thrombi. However, AF can also be a simple 'marker of risk', with a non-causal association between the arrhythmia and stroke, the latter being possibly related to atheroemboli from the aorta, the carotid arteries or from other sources.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 24499075     DOI: 10.1111/ijcp.12326

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  6 in total

Review 1.  Management of atrial fibrillation in bradyarrhythmias.

Authors:  Giuseppe Boriani; Luigi Padeletti
Journal:  Nat Rev Cardiol       Date:  2015-03-17       Impact factor: 32.419

Review 2.  New approaches to managing nonvalvular atrial fibrillation: what are the thromboembolic implications?

Authors:  Peter J Kudenchuk
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

3.  Do All Patients with Atrial Fibrillation Need Long-Term Anticoagulation?

Authors:  Munish Sharma; Rohit Masih; Daniel A N Mascarenhas
Journal:  Clin Pract       Date:  2017-07-31

Review 4.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

5.  Diagnosis of atrial fibrillation in heart failure patients with implantable cardioverter defibrillator or cardiac resynchronisation therapy.

Authors:  Barbara Dominik; Przemyslaw Mitkowski; Wojciech Zorawski; Ilona Kowalik; Adam Ciesielski
Journal:  Arch Med Sci       Date:  2021-03-25       Impact factor: 3.318

6.  Risk of Dementia Associated With Atrial Cardiopathy: The ARIC Study.

Authors:  Michelle C Johansen; Wendy Wang; Michael Zhang; David S Knopman; Chiadi Ndumele; Thomas H Mosley; Elizabeth Selvin; Amil M Shah; Scott D Solomon; Rebecca F Gottesman; Lin Yee Chen
Journal:  J Am Heart Assoc       Date:  2022-08-10       Impact factor: 6.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.